Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 398,904
  • Shares Outstanding, K 246,237
  • Annual Sales, $ 1,200 K
  • Annual Income, $ -177,120 K
  • 60-Month Beta 1.27
  • Price/Sales 346.65
  • Price/Cash Flow N/A
  • Price/Book 4.94
Trade LXRX with:

Options Overview Details

View History
  • Implied Volatility 140.03% ( +2.46%)
  • Historical Volatility 109.42%
  • IV Percentile 66%
  • IV Rank 13.16%
  • IV High 943.12% on 10/03/23
  • IV Low 18.27% on 01/11/24
  • Put/Call Vol Ratio 0.54
  • Today's Volume 1,096
  • Volume Avg (30-Day) 596
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 96,001
  • Open Int (30-Day) 93,749

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.17
  • Growth Rate Est. (year over year) -17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6100 +1.24%
on 04/17/24
2.5900 -37.07%
on 03/21/24
-0.8900 (-35.32%)
since 03/18/24
3-Month
1.2400 +31.45%
on 01/19/24
3.7300 -56.30%
on 02/16/24
+0.3300 (+25.38%)
since 01/18/24
52-Week
0.9200 +77.17%
on 11/10/23
3.7890 -56.98%
on 05/05/23
-0.9700 (-37.31%)
since 04/18/23

Most Recent Stories

More News
Lexicon: Q4 Earnings Snapshot

Lexicon: Q4 Earnings Snapshot

LXRX : 1.6300 (+0.62%)
3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts

If a trio of Wall Street analysts is correct, three lesser-known stocks could skyrocket in the new year.

COMP : 3.26 (-2.40%)
PLUG : 2.71 (-0.73%)
LXRX : 1.6300 (+0.62%)
NVAX : 3.89 (unch)
3 of the Fastest-Growing Stocks on the Planet in 2024

These hypergrowth stocks are expected to deliver sales growth of up to 1,106% in the new year.

COMP : 3.26 (-2.40%)
LCID : 2.44 (+0.83%)
LXRX : 1.6300 (+0.62%)
NKLA : 0.6600 (+2.58%)
7 Magnificent Stocks That Can Double Your Money in 2024

Triple-digit returns could be just a click of the buy button away.

COMP : 3.26 (-2.40%)
FSLY : 12.38 (-1.12%)
NVAX : 3.89 (unch)
FVRR : 19.82 (-1.44%)
STNE : 15.26 (+0.07%)
PUBM : 21.54 (-0.14%)
LXRX : 1.6300 (+0.62%)
MTCH : 32.22 (-0.19%)
3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street

Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year.

COMP : 3.26 (-2.40%)
PLUG : 2.71 (-0.73%)
LXRX : 1.6300 (+0.62%)
SAVA : 21.19 (-0.38%)
Lexicon: Q3 Earnings Snapshot

Lexicon: Q3 Earnings Snapshot

LXRX : 1.6300 (+0.62%)
Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027

EQNX::TICKER_START (OTCPK:CNER),(NYSE:NVO),(NASDAQ:TNDM),(NASDAQ:DXCM),(NASDAQ:LXRX) EQNX::TICKER_END

CNER : 0.0120 (unch)
NVO : 122.75 (-1.43%)
TNDM : 30.93 (-2.58%)
DXCM : 134.30 (+0.33%)
LXRX : 1.6300 (+0.62%)
Why Shares of Lexicon Pharmaceuticals Are Up Tuesday

Express Scripts will give its clients access to Lexicon's first approved therapy.

BMY : 48.30 (+0.96%)
LXRX : 1.6300 (+0.62%)
Lexicon: Q2 Earnings Snapshot

Lexicon: Q2 Earnings Snapshot

LXRX : 1.6300 (+0.62%)
Why Lexicon Pharmaceuticals Stock Crashed This Week

A capital raise weighed on the company's stock.

LLY : 745.95 (-0.64%)
LXRX : 1.6300 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 1.8100
2nd Resistance Point 1.7700
1st Resistance Point 1.7000
Last Price 1.6300
1st Support Level 1.5900
2nd Support Level 1.5500
3rd Support Level 1.4800

See More

52-Week High 3.7890
Fibonacci 61.8% 2.6930
Fibonacci 50% 2.3545
Fibonacci 38.2% 2.0160
Last Price 1.6300
52-Week Low 0.9200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar